Arcutis Biotherapeutics, INC Form 4 insider transactions

Patrick Burnett, See Remarks of Arcutis Biotherapeutics, Inc., sold 15,000 shares of common stock on August 11, 2026.

Patrick Burnett, See Remarks of Arcutis Biotherapeutics, Inc., sold 955 shares of common stock on August 3, 2026 for $26.12 per share.

Masaru Matsuda, See Remarks of Arcutis Biotherapeutics, Inc., sold 1,230 shares of common stock on August 3, 2026 for $26.12 per share.

Todd Watanabe, See Remarks and a Director of Arcutis Biotherapeutics, Inc., sold 4,375 shares of common stock on August 3, 2026 for $26.12 per share.

Christopher Peetz, a Director of Arcutis Biotherapeutics, Inc., reported multiple transactions in common stock on July 15, 2026.

Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc., sold 4,730 shares of common stock on July 15, 2026 for $26.91 per share.

Director Sue-Jean Lin sold 4,946 shares of Arcutis Biotherapeutics, Inc. (ARQT) pursuant to a 10b5-1 trading plan.

Director Howard G. Welgus exercised stock options and sold shares of Arcutis Biotherapeutics, Inc. under a 10b5-1 plan.

Director Patrick J. Heron filed an amendment to correct a scrivener's error regarding his indirect beneficial ownership of Arcutis Biotherapeutics shares.

Director Patrick J. Heron was granted 5,778 restricted stock units and 16,667 stock options as part of his annual director compensation.

Arcutis Biotherapeutics director Sue-Jean Lin was granted 5,778 restricted stock units and 16,667 stock options.

Arcutis Biotherapeutics director Howard G. Welgus was granted 5,778 restricted stock units and 16,667 stock options.

Director Keith Leonard acquired 5,778 restricted stock units and 16,667 stock options as part of his annual director compensation.

Director Terrie Curran was granted 5,778 restricted stock units and 16,667 stock options as part of annual director compensation.

Director Amit Munshi was granted 5,778 restricted stock units and 16,667 stock options as part of annual director compensation.

Director Halley E. Gilbert was granted 5,778 restricted stock units and 16,667 stock options as part of annual director compensation.

Director Neha Krishnamohan was granted 5,778 restricted stock units and 16,667 stock options as part of annual director compensation.

Arcutis Biotherapeutics CFO Latha Vairavan sold 435 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett sold 222 shares of common stock to satisfy tax withholding obligations.

Arcutis Biotherapeutics EVP and Chief Legal Officer Masaru Matsuda sold 8,256 shares of common stock via a 10b5-1 trading plan.

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett sold 684 shares to satisfy tax withholding obligations.

Arcutis Biotherapeutics CFO Latha Vairavan sold 1,341 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics CEO Todd Watanabe sold 3,172 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics director Howard G. Welgus sold 7,144 shares of common stock via a pre-arranged 10b5-1 trading plan.

Howard G. Welgus, a Director at Arcutis Biotherapeutics, Inc., reported a sale of 10,000 shares of common stock on April 1, 2026, executed under a pre-established 10b5-1 trading plan.

Arcutis Biotherapeutics Director Keith R. Leonard exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for a weighted average price of $25.6518 per share under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' Chief Commercial Officer, Larry Todd Edwards, reported new equity grants and subsequent tax-related stock sales.

Arcutis Biotherapeutics CEO Todd Watanabe reported the acquisition of new equity awards and sales of shares to cover tax obligations.

Arcutis Biotherapeutics' EVP and Chief Legal Officer, Masaru Matsuda, reported the acquisition of new restricted stock units and stock options, alongside sales of common stock, some for tax obligations.